Adding Concurrent Chemotherapy Significantly Improves the Survival of Stage II-IVb Nasopharyngeal Carcinoma Patients Treated With Concurrent Anti-EGFR Agents

OBJECTIVE: Anti-EGFR Targeted agents were found to be capable of modulating the antitumor immunity in head and neck cancer and become more and more frequently used in the treatment of nasopharyngeal carcinoma(NPC). We aimed to explore whether adding concurrent chemotherapy influences the survival ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Zi-Kun, Chen, Xu-Yin, Liu, Si-Han, Liu, You-Ping, You, Rui, Huang, Pei-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718697/
https://www.ncbi.nlm.nih.gov/pubmed/34976847
http://dx.doi.org/10.3389/fonc.2021.814881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718697/
https://www.ncbi.nlm.nih.gov/pubmed/34976847
http://dx.doi.org/10.3389/fonc.2021.814881

Ejemplares similares